COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00077025
Recruitment Status : Completed
First Posted : February 11, 2004
Last Update Posted : July 16, 2014
Information provided by (Responsible Party):

Brief Summary:
This study is being carried out to see if treatment with ZD1839 (Gefitinib) combined with Arimidex (Anastrozole) has improved efficacy over Arimidex alone in preventing progression of metastatic breast cancer.

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Gefitinib Drug: Anastrozole Phase 2

Detailed Description:
This is a phase II, multicenter, double-blind, randomized, placebo-controlled trial. Patients will be randomized in a double-blind manner in a 1:1 ratio to receive either 250 mg/day ZD1839 or matched placebo in combination with 1 mg/day anastrozole. The dose of ZD1839 has been selected based on clinical studies in other tumor types suggesting identical efficacy together with a better toxicity profile in patients treated at 250 mg compared to 500 mg/day. The 1 mg dose of anastrozole is the standard approved dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 174 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Phase II Multicenter, Double-Blind, Randomized Trial Comparing Anastrozole (ZD1033, Arimidex™)-Placebo to the Combination Anastrozole-ZD1839 (Gefitinib, IRESSA™) in Postmenopausal Patients With Estrogen Receptor (ER) and/or Progesterone Receptor (PgR) Metastatic Breast Cancer
Study Start Date : January 2004
Actual Primary Completion Date : May 2013
Actual Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Active Comparator: Anastrozole-placebo
Anastrozole (ZD1033, Arimidex)-Placebo
Drug: Anastrozole
1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
Other Name: Arimidex

Active Comparator: Anastrozole-ZD1839
Anastrozole (ZD1033, Arimidex)-ZD1839 (gefitinib, IRESSA)
Drug: Gefitinib
ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
Other Name: IRESSA

Primary Outcome Measures :
  1. Time to progression [ Time Frame: Duration of study ]
    To estimate TTP in the 2 treatment arms of postmenopausal patients with newly diagnosed metastatic breast cancer

Secondary Outcome Measures :
  1. Objective response rate [ Time Frame: Duration of Study ]
    To estimate the ORR (complete response [CR] and partial response [PR] as defined by RECIST for the 2 treatment arms

  2. Overall clinical benefit rate [ Time Frame: Duration of Study ]
    To estimate the clinical benefit rates (CBR; defined as CR+PR[as per RECIST]+stable disease [SD]>24 weeks) for the 2 treatment arms

  3. Overall survival [ Time Frame: Duration of Study ]
    To estimate overall survival (OS) for each of the 2 treatment arms

  4. Safety [ Time Frame: Duration of Study ]
    To compare the tolerability of anastrozole/placebo to that of anastrozole/ZD1839

  5. Pharmacokinetic variables [ Time Frame: Duration of Study ]
    To determine steady-state plasma trough concentrations of anastrozole in all patients. To determine steady-state trough concentrations of ZD1839 and to relate values to historical data

  6. Biomarker objectives [ Time Frame: Duration of Study ]
    To obtain tumor tissue and blood samples for biologic studies in the limited population available and measure expression of markers that may potentially correlate with response to treatment in this patient population

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Female postmenopausal patients aged 18 years or older with newly diagnosed metastatic breast cancer.
  • Patients with recurrent disease during or after adjuvant tamoxifen or patients who are hormone therapy naïve are eligible for this trial.
  • A paraffin embedded tumor tissue block or slides from either the metastatic or primary tumor site is required.

Exclusion Criteria:

  • Patients cannot be on hormone replacement therapy while on study.
  • Prior chemotherapy received for metastatic disease is not allowed.
  • Previous treatment with tyrosine kinase inhibitors or aromatase inhibitors is not allowed.
  • Patients who have evidence of an active interstitial lung disease are not eligible.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00077025

Layout table for location information
United States, California
Research Site
La Jolla, California, United States
Research Site
San Diego, California, United States
United States, Florida
Research Site
Orlando, Florida, United States
United States, Louisiana
Research Site
Lafayette, Louisiana, United States
United States, Maryland
Research Site
Rockville, Maryland, United States
United States, Missouri
Research Site
Columbia, Missouri, United States
United States, Nebraska
Research Site
Omaha, Nebraska, United States
United States, Nevada
Research Site
Las Vegas, Nevada, United States
United States, New Jersey
Research Site
Voorhees, New Jersey, United States
United States, New Mexico
Research Site
Albuquerque, New Mexico, United States
United States, New York
Research Site
Lake Success, New York, United States
United States, Ohio
Research Site
Cincinnati, Ohio, United States
United States, Pennsylvania
Research Site
Allentown, Pennsylvania, United States
United States, South Dakota
Research Site
Sioux Falls, South Dakota, United States
United States, Texas
Research Site
Houston, Texas, United States
Research Site
Temple, Texas, United States
Research Site
Cali, Colombia
Research Site
Aguascalientes, Mexico
Research Site
Guadalajara, Mexico
Research Site
Morelia, Mexico
Research Site
Barcelona, Venezuela
Research Site
Barquisimeto, Venezuela
Research Site
Caracas, Venezuela
Research Site
Maracaibo, Venezuela
Research Site
Puerto Ordaz, Venezuela
Research Site
San Cristobal, Venezuela
Research Site
Valencia, Venezuela
Sponsors and Collaborators
Layout table for investigator information
Study Director: Iressa Medical Science Director, MD AstraZeneca
Additional Information:
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00077025    
Other Study ID Numbers: 1839US/0713
First Posted: February 11, 2004    Key Record Dates
Last Update Posted: July 16, 2014
Last Verified: July 2014
Keywords provided by AstraZeneca:
metastatic breast cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Hormonal
Aromatase Inhibitors
Steroid Synthesis Inhibitors
Estrogen Antagonists
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs